Comparison of Efficacies of Dose Dense Paclitaxel Plus Carboplatin and Conventional Paclitaxel Plus Carboplatin in the Treatment of Epithelial Ovarian Cancer
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, vol.31, no.4, pp.239-245, 2021 (SCI-Expanded, Scopus, TRDizin)
- Publication Type: Article / Article
- Volume: 31 Issue: 4
- Publication Date: 2021
- Doi Number: 10.4999/uhod.215771
- Journal Name: UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, EMBASE, TR DİZİN (ULAKBİM)
- Page Numbers: pp.239-245
- Keywords: Carboplatin, Chemotherapy, Ovarian epithelial carcinoma, Paclitaxel, Survival, PHASE-III TRIAL, PRIMARY CYTOREDUCTIVE SURGERY, SINGLE-AGENT PACLITAXEL, EVERY 3 WEEKS, 1ST-LINE TREATMENT, FALLOPIAN-TUBE, CLINICAL-TRIALS, OPEN-LABEL, SURVIVAL, CHEMOTHERAPY
- Hacettepe University Affiliated: Yes
Abstract
This study aims to compare efficacy of dose dense and conventionally dosed paclitaxel-carboplatin regimens in the first-line treatment of epithelial ovarian cancer (EOC). We evaluated the medical records of women with EOC followed in Zekai Tahir Burak Women's Health Training and Research Hospital between 2007-2019 retrospectively. The patients with Eastern Cooperative Oncology Group Performance Status of 0-1-2, and stages of IC-IV, without previous treatments, who had undergone primary cytoreductive surgery were included. All patients had received either dose dense paclitaxel-carboplatin (paclitaxel 80 mg/m(2) given on days 1, 8, and 15 plus carboplatin Area Under the Curve: 5 on day 1 of the 21 day cycle) or conventionally dosed paclitaxel-carboplatin (paclitaxel 175 mg/m(2) plus carboplatin Area Under the Curve: 5 on day 1 of the 21 day cycle) regimens in the first line treatment. Baseline clinicopathological features, progression-free survival, and overall survival were evaluated. This study included data of 133 patients. Forty patients had received dose dense regimen while 93 had conventionally dosed regimen. Median progression-free survival of the dose dense group [34.4 months (31.7 - 37.03)] was significantly longer than the conventional group [25.5 months (19.9-30.9)] [HR=0. 55 (95% CI, 0.31 - 0.95), p=0.03]. Median overall survival was 88.2 months (28.3 - 148.3) in the dose dense group and 76.5 months (63.3 - 89.7) in conventional group (p=0.102).We have found improved progression-free survival in the first-line treatment of EOC with dose dense regimen compared to conventionally dosed regimen. Overall survival was longer in the dose dense group despite being not significant.